top of page
Langen_ThemeDay_Small.jpg

The Next Frontiers in ATMP
Development

PROGRAMME

Check this page regularly for updates

THURSDAY 27 APRIL

10:00-11:00

Registration

11:00-11:30

Opening

Chair: Zoltan Ivics, Paul-Ehrlich-Institut, Langen

 

11:00-11:10  Zoltan Ivics, Paul-Ehrlich-Institut, Langen

Welcome and opening remarks

11:10-11:30  Martina Schüssler-Lenz, Paul-Ehrlich-Institut, Langen

INV01:  The life cycle management of Advanced Therapy Medicinal Products (ATMPs)

11:30-12:45 

Session 1: Accelerating innovation in gene and cell therapy

Chair:

 

11:30-11:50  Christopher Baum, BIH Berlin

INV02: Building an ecosystem for innovation in the field of cell and gene therapy

11:50-12:10  Tobias Helmstorf, Bayer, Berlin

INV03:  

12:10-12:30  John Bell, The Ottawa Hospital Research Institute

INV04: The BioCanRx Consortium

12:30-12:45  Q&A

12:45-13:45

Lunch

13:45-15:00 

Session 2: Trends in ATMP Manufacturing

Chair:

 

13:45-14:05  Mario Assenmacher, Miltenyi Biotec GmbH

INV05: Advancing CAR/TCR T cell processing platforms towards decentral manufacturing

14:05-14:25  Qasim Rafiq, University College London

INV06:  Automated process intensification and manufacturing strategies for ATMPs

14:25-14:45  Simon Hort, Fraunhofer IPT

INV07: The AIDPATH Consortium: How can digitalisation and automation enable large-scale application of CAR-T cell therapies? 

14:45–15:00  Q&A

15:00-16:20 

Session 3: Academic Development of ATMPs

Chair:

 

15:00-15:15  Claire Booth, University College London

INV08: The AGORA Initiative

15:15-15:30  Alessandro Aiuti, San Raffaele Scientific Institute, Milano

INV09:  A novel platform approach for the treatment of lysosomal storage diseases with skeletal involvement

15:30-15:50  Özcan Met, National Center for Cancer Immune Therapy, Herlev

INV10: Manufacture of adoptive cell therapies at an academic cancer center

15:50-16:00  Caroline Pothet, EMA, Amsterdam

INV11:  EMA’s pilot for academic and non-profit ATMP developers

16:00-16:20  Q&A

16:20-16:40

Coffee Break

16:40-18:00 

Roundtable Discussion

T2 EVOLVE Regulatory Focus: Progressing the Parent-Child IND Concept

Chair:

Thursday

Friday 28 April

08:30-09:00

Registration

9:00–10:40

Session 4: What’s hot: Preclinical and Clinical Developments to Accelerate ATMP 

Chair:

 

9:00-9:20  Emmanuel Donnadieu, INSERM, Paris

INV12:  Predicting safety and efficacy of engineered T cells using ex vivo human models

9:20-9:40  Julio Delgado, Hospital Clínic de Barcelona

INV13:  ATMPs: from bench to bedside (through the regulator’s desk)

9:40-10:00  Anna Maria Veiga, IDIBELL, Barcelona

INV14:  Predicting safety and efficacy of engineered T cells using ex vivo human models

10:00-10:20  

INV15:  

10:20-10:40  Q&A

10:40-11:00

Coffee

11:00-13:10 

Session 5: Improving Awareness and Access to Cell and Gene Therapies

Chair:

 

11:00-11:20  Clare Blackburn, University of Edinburgh

INV16: The EuroGCT Consortium: Meeting information needs of all stakeholders in cell and gene therapy

11:20-11:40  

INV17:  

11:40-12:00  

INV18: 

12:00–12:20  Alexander Natz, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Brussels

INV19:  Reimbursement of ATMPs: Current roadblocks and the implications of the EU HTA

12:20-12:40  

INV20: 

12:40-13:10  Q&A

13:10-13:15

Closing Remarks

Chair: Zoltan Ivics, Paul-Ehrlich-Institut

13:15-14:00

Lunch

Friday
bottom of page